{"name":"Surrozen","slug":"surrozen","ticker":"SRZN","exchange":"NASDAQ","domain":"surrozen.com","description":"Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and com","hq":"South San Francisco, CA","founded":0,"employees":"44","ceo":"Craig Parker","sector":"Regenerative Medicine / Biotech","stockPrice":29.98,"stockChange":-0.16,"stockChangePercent":-0.53,"marketCap":"$348M","metrics":{"revenue":7494000,"revenueGrowth":408.6,"grossMargin":-291.8,"rdSpend":29365000,"netIncome":-242026000,"cash":106910000,"dividendYield":0,"peRatio":-7.5,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-27","type":"trial","headline":"Surrozen Announces Positive Interim Results from Phase 1b Clinical Trial of SRW200 in Patients with Idiopathic Pulmonary Fibrosis","summary":"Surrozen reported positive interim results from a Phase 1b clinical trial of SRW200 in patients with idiopathic pulmonary fibrosis. The trial demonstrated a statistically significant reduction in lung function decline.","drugName":"SRW200","sentiment":"positive"},{"date":"2022-11-14","type":"deal","headline":"Surrozen Announces Collaboration with Gilead Sciences to Develop Novel Wnt-Targeting Therapies for Fibrosis and Cancer","summary":"Surrozen entered into a collaboration with Gilead Sciences to develop novel Wnt-targeting therapies for fibrosis and cancer. The collaboration aims to leverage Surrozen's Wnt-targeting antibodies with Gilead's expertise in fibrosis and cancer.","drugName":"SRW200","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPMW9GSzJVN2xHVENXQlVKTE9rQVBmeURIXzN5MEUzcnk1OE9IOFVROWE3dEdRTl9RVGd4WjZvOS1aOFJjN0tGcDFZZnV4a2wxLTc5ZkNFempVY3JTa0pYb1hURi1tT2M5ekYyRnJVV3ZaQnZnd3A5Z2NXSzB5SzZQbFVOSGhOb1Q3ZnA5TlBnUks3RnN5Y182VzB5X1FPVkRFMGozOE9ULTdEUTRJRmpHck1B?oc=5","date":"2026-04-01","type":"pipeline","source":"Stock Titan","summary":"Executive pay and board elections headline Surrozen (NASDAQ: SRZN) 2026 meeting - Stock Titan","headline":"Executive pay and board elections headline Surrozen (NASDAQ: SRZN) 2026 meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPMjhlX2l5VTEtV252RHp1ZkRKVkE3c2FKTDBZRTJmV3NIS3BSdXd4OGFKRTIzT0hjd29KVWVQRDdOT0dzbHZtUDZzQUs5ZGZLTVFkbFZTc1RISDliSjNKdjNjTVI1aEZ6enhwb3FZcWtZZXhuZHdISTVveWN5ak9WTm1ISDEtYlRVNVZuQUtRVEMzMC1WRlI2SVdsY0hZdGRrZU1STDJrMHBKemxlSUE?oc=5","date":"2026-04-01","type":"pipeline","source":"Stock Titan","summary":"Surrozen (SRZN) EVP Li Yang donates 1,666 common shares in Form 4 - Stock Titan","headline":"Surrozen (SRZN) EVP Li Yang donates 1,666 common shares in Form 4","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxQWkM3QkM1MEtLMWw0U2c4S3JiTXpmdWhFRXN1b0cxTGRwbGJ0TnpmMHgzZkI3dThSRzdGZ0M5WFlBTUFUdk5uNDZYbHdUX0ZETUM2Z3pMbUJ5Q1gzSG81cmw3b1FHM3FteHNYMlRMbmR0TFlXNjc4WDg1UDNWMmN3bEEwT1VOMUdMbjhLTmdpTUM0Q0VBSzB1Y29nQnVKYzlManhyZ1RwYlBwWHVJNWJoWmFFTG1nZ2xGZy0wUkxOcmNQUGkxVklKRWpzUHNHb2xGY2M4bXB1M1poSUZMMjl3YU9R?oc=5","date":"2026-03-25","type":"deal","source":"The Globe and Mail","summary":"Cantor Fitzgerald Sticks to Their Buy Rating for Surrozen (SRZN) - The Globe and Mail","headline":"Cantor Fitzgerald Sticks to Their Buy Rating for Surrozen (SRZN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxQTzZRaGFqaUwyUHNDQmV4NGVSNVZOLWZ2SExtSVBONW5zVnN4bXl2ZE5aeGJvaHBOQU9ZVkk1NU93YXlwWDZEVkpXQTdzZ3F1ZXFpMzN0VWNvbW11bFNISG9zLXBhTjExTktScXJlc3dvWmlyTENfdi1kRktrcjFzdzE0aW1tTDVRV1dFemFnNU1NSnNFLU5iOHBlelcwQU1CMUJGRF9NbHdxSTR2UDVpMUVqc0xKQ29ERTNsc0FDczlMM01JVTJnSVpkNXBIWWVLN09YU1QtNUhkZ2UxbUVUQm51WQ?oc=5","date":"2026-03-25","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Are Bullish on Top Healthcare Stocks: CSL (CMXHF), Surrozen (SRZN) - The Globe and Mail","headline":"Analysts Are Bullish on Top Healthcare Stocks: CSL (CMXHF), Surrozen (SRZN)","sentiment":"neutral"},{"date":"2026-03-23","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPbHVPdnotZUF4WE8zTlpUbVEzeGNoOHowVVlJc1VBSXFHLTRZN2pXQ0d6VFVoXzRjTnd2aXZUTUhndGY5WmpjTHNYMlBFbWhVU3NwZXd1ekJCb2V1QzRWVWJMd2tELTkwZjVDbm9nWmJYUEpWbENmVzBkcUdyOTByMg?oc=5","date":"2026-01-16","type":"pipeline","source":"MarketBeat","summary":"Top MindWalk (HYFT) Competitors 2026 - MarketBeat","headline":"Top MindWalk (HYFT) Competitors 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgJBVV95cUxObWhzcUV5UEJNNVY1ZEVpb2RMUWxZTFVjYklzQ1lfVkdHSTRLUXVEZlFqS1IwSVZVZ1RtWEtGSWNmZjRxS01nU0k3d3ZxdTdJVlFrWG5EcEU0V3ZfUWRwYWpna0xQNkRTTTdlWTdDa3BoZUZzS1ZMTWlVWDFURkVkM2JzZDNSQ2FzRVFGdFlZS0drT0JVUk5QQUU1Um9xTjlvRkJ3S3hoWWpjb0JXdklPa1g2WU1tRlBJUndOaGM2OWhNZGRvNnVMQk9FdXptYllveUdsTG1GQmk0aTRkLVRNUXBvNXh2SXNZY1B0NHRLR055bmgzN0UtRkdYOHk5XzN1NVJncFZWQjU2ZkhuMzdjYzhJLV9TdGRiZWFFN0JudTFpQVVFX2lNZlNrZFdiUTA0V0h5eHFlLVpHYlBIVWdUcmdZa1hOZjVwVkx5XzRB?oc=5","date":"2025-03-24","type":"pipeline","source":"GlobeNewswire","summary":"Surrozen Announces an Oversubscribed $175 Million Private - GlobeNewswire","headline":"Surrozen Announces an Oversubscribed $175 Million Private","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTFBBVlg2Y25EYk8yOXdBa3JjT0Vlcy1NVjI2YWdTMFJrTGxseUJvMU9KMS1ybVZYcTNFd0xsamJqV1ZaU2VTSmFEd2NjMThGTFAwREV0amNmUWF0VHg3S3hMOGVYNnFnUQ?oc=5","date":"2024-05-13","type":"pipeline","source":"MarketBeat","summary":"Surrozen (SRZN) Stock Forecast and Price Target 2026 - MarketBeat","headline":"Surrozen (SRZN) Stock Forecast and Price Target 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE9waXMzWVpVbFhZUndwRldQZnhKY2JkUHAzUW5lNmVuWV9mX1Q1VzRSMkhzTmZXNk9xRnJTRUlnNnU3R0U4SkJmZFRnNE5oM05wa1E?oc=5","date":"2023-07-09","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Surrozen, Inc. (SRZN) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Surrozen, Inc. (SRZN) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE03N2ViNU51akFzSnk4ZEF3SVVFTnZ6M2wyTWdVSTZ5WUhNT0M3WGRRNHVvc2F0UnBZTzBJbkl4eGhZYXBObmdZbkN1YUZlaVh6elE?oc=5","date":"2021-08-28","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Surrozen, Inc. (SRZN) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Surrozen, Inc. (SRZN) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE5pY3l6eURFMnFqTnVDRURzR09jWUx4Y1FoU0hVZDRiRnNzM2Izd1ZIQjhnclFLSXl3MW01alZvbWRsa2tXcXFNa1ZJVUhRRFUwRUdtMXRWb2ZsUQ?oc=5","date":"2021-08-24","type":"pipeline","source":"MarketBeat","summary":"Surrozen (SRZN) Stock Price, News & Analysis $SRZN - MarketBeat","headline":"Surrozen (SRZN) Stock Price, News & Analysis $SRZN","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Biogen","Regeneron Pharmaceuticals"],"therapeuticFocus":["Fibrosis","Cancer"],"financials":{"source":"sec_edgar+yahoo","revenue":3477000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":3477000,"period":"2025-12-31"},{"value":10655000,"period":"2024-12-31"},{"value":10655000,"period":"2024-12-31"},{"value":0,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":29365000,"rdSpendHistory":[{"period":"2025-12-31","value":29365000},{"period":"2024-12-31","value":21132000},{"period":"2023-12-31","value":27230000},{"period":"2022-12-31","value":37013000}],"sgaSpend":16204000,"operatingIncome":-42092000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-42092000},{"period":"2024-12-31","value":-25539000},{"period":"2023-12-31","value":-43028000},{"period":"2022-12-31","value":-44339000}],"netIncome":-242026000,"netIncomeHistory":[{"period":"2025-12-31","value":-242026000},{"period":"2024-12-31","value":-63564000},{"period":"2023-12-31","value":-43042000},{"period":"2022-12-31","value":-36004000}],"eps":-32.37,"epsHistory":[{"period":"2025-12-31","value":-32.37},{"period":"2024-12-31","value":-21.67},{"period":"2023-12-31","value":-21.33},{"period":"2022-12-31","value":-15.6}],"cash":89245000,"cashHistory":[{"period":"2025-12-31","value":89245000},{"period":"2024-12-31","value":34565000},{"period":"2023-12-31","value":36043000},{"period":"2022-12-31","value":24690000}],"totalAssets":98726000,"totalLiabilities":286488000,"totalDebt":6639000,"equity":-187762000,"operatingCashflow":-30244000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-30244000},{"period":"2024-12-31","value":-17628000},{"period":"2023-12-31","value":-40363000},{"period":"2022-12-31","value":-44145000}],"capex":-128000,"capexHistory":[{"period":"2025-12-31","value":-128000},{"period":"2024-12-31","value":-26000},{"period":"2023-12-31","value":-398000},{"period":"2022-12-31","value":-728000}],"freeCashflow":-30372000,"dividendsPaid":null,"buybacks":0,"employees":44,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":4176000,"ebit":-12639000,"ebitda":-12594000,"period":"2025-12-31","revenue":528000,"epsBasic":null,"netIncome":-183159000,"rdExpense":8991000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-12639000},{"sga":4094000,"ebit":-10885000,"ebitda":-10824000,"period":"2025-09-30","revenue":983000,"epsBasic":-8.36,"netIncome":-71643000,"rdExpense":7774000,"epsDiluted":-8.36,"grossProfit":null,"operatingIncome":-10885000},{"sga":3958000,"ebit":-9017000,"ebitda":-8880000,"period":"2025-06-30","revenue":983000,"epsBasic":2.55,"netIncome":39746000,"rdExpense":6042000,"epsDiluted":2.55,"grossProfit":null,"operatingIncome":-9017000},{"sga":3976000,"ebit":-9551000,"ebitda":-9257000,"period":"2025-03-31","revenue":983000,"epsBasic":-7.43,"netIncome":-26970000,"rdExpense":6558000,"epsDiluted":-7.43,"grossProfit":null,"operatingIncome":-9551000},{"sga":3897000,"ebit":-8592000,"ebitda":-8270000,"period":"2024-12-31","revenue":655000,"epsBasic":null,"netIncome":-28039000,"rdExpense":5350000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-8592000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.44,"netIncome":null,"rdExpense":null,"epsDiluted":-0.44,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":29.98,"previousClose":30.14,"fiftyTwoWeekHigh":35,"fiftyTwoWeekLow":5.9,"fiftyTwoWeekRange":"5.9 - 35.0","fiftyDayAverage":28.91,"twoHundredDayAverage":19.58,"beta":0,"enterpriseValue":249804576,"forwardPE":-7.5,"priceToBook":-1.56,"priceToSales":46.45,"enterpriseToRevenue":33.33,"enterpriseToEbitda":-5.85,"pegRatio":0,"ebitda":-42689000,"ebitdaMargin":0,"freeCashflow":-27378124,"operatingCashflow":-33460000,"totalDebt":6778000,"debtToEquity":0,"currentRatio":11.91,"returnOnAssets":-22.8,"returnOnEquity":0,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":4,"targetMeanPrice":42.5,"targetHighPrice":44,"targetLowPrice":40,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":3.2,"institutionHeldPercent":100.1,"sharesOutstanding":11610371,"floatShares":4842454,"sharesShort":565307,"shortRatio":4.35,"shortPercentOfFloat":4.9,"epsTrailing":-36.59,"epsForward":-3.98,"revenuePerShare":0.81,"bookValue":-19.21,"officers":[{"age":63,"name":"Mr. Craig C. Parker M.B.A.","title":"CEO, President & Director"},{"age":45,"name":"Mr. Charles  Williams","title":"COO & Corporate Secretary"},{"age":56,"name":"Dr. Yang  Li Ph.D.","title":"Executive Vice President of Research"},{"age":null,"name":"Dr. K. Christopher  Garcia Ph.D.","title":"Co-Founder & Member of Scientific Advisory Board"},{"age":75,"name":"Dr. Roeland  Nusse Ph.D.","title":"Co-Founder & Member of Scientific Advisory Board"},{"age":null,"name":"Dr. Calvin  Kuo M.D., Ph.D.","title":"Co-Founder & Member of Scientific Advisor"},{"age":35,"name":"Mr. Andrew  Maleki","title":"Chief Financial Officer"},{"age":null,"name":"Dr. Daniel L. Chao M.D., Ph.D.","title":"VP & Head of Clinical Development"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.surrozen.com","phone":"650 489 9000"}}